Company Watch

Jubilant enters into drug discovery pact with Amgen

Our News Bureau - Mumbai

Jubilant Biosys, a wholly owned subsidiary of Jubilant Organosys has recently entered into a drug discovery agreement with US based biotech company Amgen. Under the partnership Amgen and Jubilant will collaborate for an initial term of three years to develop a portfolio of novel drugs in new target areas of interest across multiple therapeutic areas. The financial terms include a combination of research funding and success-based milestones paid to Jubilant during pre-clinical and clinical development for multiple projects undertaken by the collaboration. As per the agreement, Jubilant will develop early preclinical candidates at its research centre at Bangalore and Amgen will pursue later stage pre-clinical and clinical development and commercialisation of the drugs in global markets.

Commenting on the development, Shyam S Bhartia, Chairman and Managing Director and Hari S Bhartia, Co-Chairman and Managing Director of Jubilant Organosys said, "We are very pleased to expand our relationship with Amgen. This collaboration leverages the innovation capabilities of Jubilant Biosys in pharmaceutical discovery and preclinical development, combining these strengths with Amgen, the world's largest research driven Biotech company, to deliver cost-effective new products that will help patients around the world. This partnership continues to demonstrate Jubilant's strategy to be India's largest innovation driven integrated pharmaceutical service provider supporting the global pharmaceutical Industry."